Venous Leg Ulcers Market to Exhibit Substantial Growth During the Forecast Period (2022-32) | Key Players – TICEBA, RHEACELL, MediWound, Reponex, Energenesis, Solascure, TR Therapeutics, Promore

November 29 17:54 2022
Venous Leg Ulcers Market to Exhibit Substantial Growth During the Forecast Period (2022-32) | Key Players - TICEBA, RHEACELL, MediWound, Reponex, Energenesis, Solascure, TR Therapeutics, Promore
Delveinsight Business Research LLP
As per DelveInsight, the Venous Leg Ulcer therapeutics market is anticipated to evolve immensely in the coming years owing to the increase in the number of patients suffering from Venous Leg Ulcer in the 7MM, which would lead to higher adoption of therapeutic drugs.

DelveInsight’s “Venous Leg Ulcers Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Venous Leg Ulcers market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Venous Leg Ulcers market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Venous Leg Ulcers Market

Venous Leg Ulcers: An Overview

A Venous Leg Ulcers (VLU) is defined as the loss of skin below the knee on the leg or foot in the presence of venous disease. These ulcers persist for more than 6 weeks and are therefore referred to as chronic VLUs, representing the most advanced form of chronic venous disorders like varicose veins and lipodermatosclerosis.

In patients with venous disease or failure, venous pressure in the deep system falls less than normal during ambulation and rises in an orthostatic position, termed venous hypertension. There is no general consensus about the transition from venous hypertension to venous ulceration.

Venous Leg Ulcers have a negative impact on the quality of life and result in considerable costs to both patients and healthcare providers. Also, there are no uniform guidelines for assessing and managing this group of conditions, which is reaching epidemic proportions in prevalence.

Venous Leg Ulcers Market Key Facts

  • Venous ulcers (VUs) account for approximately 75% of all chronic leg ulcers and are characterized by several factors that hinder and delay healing.

  • According to a study by Nelson et al. (n.d.), between 1.5/1,000 and 3.0/1.000 people have active leg ulcers, and prevalence increases with age to about 20/1,000 people aged over 80 years.

  • Venous leg ulceration occurs secondary to venous reflux or obstruction. It affects up to 3 in 1,000 people (Nelson et al.).

  • According to the NHS, venous leg ulcer is the most common type of leg ulcer, accounting for more than 90% of all cases.

Venous Leg Ulcers Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Venous Leg Ulcers market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Venous Leg Ulcers market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Venous Leg Ulcers Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

The Report Covers the Venous Leg Ulcer Epidemiology Segmented by –

  • Total Incident and Prevalent Cases of Venous leg ulcers

  • Age-specific Cases of Venous leg ulcers

Venous Leg Ulcers Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Venous Leg Ulcers market or expected to get launched during the study period. The analysis covers the Venous Leg Ulcers market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Venous Leg Ulcers Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Venous Leg Ulcers Market Will Evolve by 2032 @

Key Companies in the Venous Leg Ulcer Market include:



  • MediWound

  • Reponex Pharmaceuticals

  • Energenesis Biomedical

  • Solascure limited

  • TR Therapeutics

  • Promore Pharma AB

  • NovaLead Pharma

And several others.

Venous Leg Ulcer therapies covered in the report include:


  • ENERGI-F703

  • EscharEx

And many more.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Venous Leg Ulcers Competitive Intelligence Analysis

4. Venous Leg Ulcers Market Overview at a Glance

5. Venous Leg Ulcers Disease Background and Overview

6. Venous Leg Ulcers Patient Journey

7. Venous Leg Ulcers Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Venous Leg Ulcers Treatment Algorithm, Current Treatment, and Medical Practices

9. Venous Leg Ulcers Unmet Needs

10. Key Endpoints of Venous Leg Ulcers Treatment

11. Venous Leg Ulcers Marketed Products

12. Venous Leg Ulcers Emerging Drugs and Latest Therapeutic Advances

13. Venous Leg Ulcers Seven Major Market Analysis

14. Attribute Analysis

15. Venous Leg Ulcers Market Outlook (In US, EU5, and Japan)

16. Venous Leg Ulcers Access and Reimbursement Overview

17. KOL Views on the Venous Leg Ulcers Market

18. Venous Leg Ulcers Market Drivers

19. Venous Leg Ulcers Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

Other Trending Healthcare Reports By DelveInsight

Venous Leg Ulcers Pipeline Insights

“Venous Leg Ulcers – Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies and 7+ drugs in the Venous Leg Ulcers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States